Fig. 2.

Time course of LS mean change from baseline in MDS-UPDRS Part II total score among all participants (pooled mITT population). The LS mean (SE) [Gocovri-placebo] treatment differences were: week 2: −1.8 (0.68) P = 0.009; week 8: −1.1 (0.68) ns; week 12: −2.0 (0.68); P = 0.004. P values are based on the comparison between Gocovri vs. placebo from the MMRM model with change from baseline as the dependent variable and the baseline value as a covariate. The model includes categorical effects for treatment group, study, and visit (weeks 2, 8, and 12), and the interaction between treatment group and visit. LS least squares, MDS-UPDRS Movement Disorder Society Unified Parkinson’s Disease Rating Scale, mITT modified intent to treat, MMRM mixed-effects model repeated measure, SE standard error